title: Cardiovascular risk in patients with type 2 diabetes.
authors.forename: Miriam
authors.initials: M
authors.lastname: Shanks
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Holmes
authors.forename: Luba
authors.initials: L
authors.lastname: Cermakova
authors.forename: Jiri
authors.initials: J
authors.lastname: Frohlich
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin